0001104659-20-097720.txt : 20200821 0001104659-20-097720.hdr.sgml : 20200821 20200821190459 ACCESSION NUMBER: 0001104659-20-097720 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200819 FILED AS OF DATE: 20200821 DATE AS OF CHANGE: 20200821 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gelone Steven P. CENTRAL INDEX KEY: 0001693064 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 201124428 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 4 1 a4.xml 4 X0306 4 2020-08-19 0 0001641640 Nabriva Therapeutics plc NBRV 0001693064 Gelone Steven P. 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 0 1 0 0 President and COO Ordinary Shares 2020-08-19 4 M 0 11250 A 352199 D Ordinary Shares 2020-08-19 4 M 0 16000 A 368199 D Ordinary Shares 2020-08-20 4 F 0 3204 0.6476 D 364995 D Ordinary Shares 2020-08-20 4 F 0 4557 0.6476 D 360438 D Restricted Share Units 2020-08-19 4 M 0 11250 0 D Ordinary Shares 11250 0 D Restricted Share Units 2020-08-19 4 M 0 16000 0 D Ordinary Shares 16000 0 D The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units. On January 31, 2018, Nabriva Therapeutics plc (the "Issuer") granted the reporting person 22,500 restricted share units ("RSUs"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the "Performance Condition"), and the remaining fifty percent (50%) of the RSUs vested on the one (1)-year anniversary of the Performance Condition. On August 2, 2018, the Issuer granted the reporting person 32,000 RSUs. Fifty percent (50%) of the RSUs vested on August 19, 2019 upon the occurrence of the Performance Condition, and the remaining fifty percent (50%) of the RSUs vested on the one (1)-year anniversary of the Performance Condition. /s/ Robert Crotty, by power of attorney 2020-08-21